Molecular Partners Reveals Preclinical Data For First Switch-Darpin Candidate MP0621 At EHA 2024
Portfolio Pulse from Benzinga Newsdesk
Molecular Partners has revealed preclinical data for its first Switch-Darpin candidate, MP0621, at EHA 2024. The data supports MP0621's potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effects. MP0621 is currently in IND-enabling studies with a Phase 1 trial in AML anticipated in 2025.
June 14, 2024 | 7:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Molecular Partners has presented promising preclinical data for MP0621, indicating its potential to selectively target cKit-positive cells and conditionally block CD47 with limited side effects. The candidate is in IND-enabling studies with a Phase 1 trial in AML expected in 2025.
The preclinical data for MP0621 is promising, showing potential efficacy and safety. This positive development could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100